APA (7th ed.) Citation

G, L., PB, C., JM, L., MJ, K., GG, L., VS, M., . . . JT, C. (2020). A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers. Blood advances, 4(4), 728. https://doi.org/10.1182/bloodadvances.2019000885

Chicago Style (17th ed.) Citation

G, Lu, Conley PB, Leeds JM, Karbarz MJ, Levy GG, Mathur VS, Castillo J, Crowther M, and Curnutte JT. "A Phase 2 PK/PD Study of Andexanet Alfa for Reversal of Rivaroxaban and Edoxaban Anticoagulation in Healthy Volunteers." Blood Advances 4, no. 4 (2020): 728. https://doi.org/10.1182/bloodadvances.2019000885.

MLA (9th ed.) Citation

G, Lu, et al. "A Phase 2 PK/PD Study of Andexanet Alfa for Reversal of Rivaroxaban and Edoxaban Anticoagulation in Healthy Volunteers." Blood Advances, vol. 4, no. 4, 2020, p. 728, https://doi.org/10.1182/bloodadvances.2019000885.